Financial Performance - For the three months ended June 30, 2024, general and administrative expenses were 1,587,060,adecreaseof11.91,800,536 in the same period of 2023[88]. - The net loss from continuing operations for the three months ended June 30, 2024, was 3,866,249,representinga7.53,598,084 in the prior year[88]. - The net loss for the six months ended June 30, 2024, was 7,727,089,anincreaseof5.87,300,909 in the same period of 2023[89]. - Net loss from continuing operations was 7,727,089forthesixmonthsendedJune30,2024,comparedto6,863,894 for the same period in 2023[104]. - Other income (expense), net decreased by approximately 152,000,or662,357,974 for the three months ended June 30, 2024, compared to 2,028,165in2023[88].−Researchanddevelopmentexpensesincreasedbyapproximately307,000, or 15%, for the three months ended June 30, 2024, primarily due to clinical trial costs related to PAS-004[96]. - Research and development expenses increased by approximately 982,000,or316.8 million from December 31, 2023, to June 30, 2024, primarily due to cash used to fund operations[103]. - Cash and cash equivalents decreased by approximately 8.4millionforthesixmonthsendedJune30,2024,comparedtoadecreaseofapproximately6.4 million for the same period in 2023[104]. - A one-for-20 reverse stock split was executed on January 2, 2024, reducing the number of authorized shares from 495 million to 100 million[85].
